The rationale for protein degradation and immunomodulation in RRMM: Latest data and clinical trials

What are the limitations of current therapies for the treatment of relapsed/refractory multiple myeloma and what is the latest evidence for emerging therapies targeting protein degradation and immunomodulation?
Prof. Cristina Gasparetto, Prof. Sagar Lonial and Prof. Sundar Jagannath share their insights.
Watch now: touchoncologyime.org/protein-...
This activity is funded by an independent medical education grant from Bristol Myers Squibb. This activity is jointly provided by USF Health and touchIME.